scholarly journals Vitamin A Supplementation and Human Immunodeficiency Virus Type 1 Shedding in Women: Results of a Randomized Clinical Trial

2002 ◽  
Vol 185 (8) ◽  
pp. 1187-1191 ◽  
Author(s):  
Jared M. Baeten ◽  
R. Scott McClelland ◽  
Julie Overbaugh ◽  
Barbra A. Richardson ◽  
Sandra Emery ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Human Immunodeficiency Virus ◽  
Vitamin A ◽  
Randomized Clinical Trial ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Vitamin A Supplementation ◽  
Immunodeficiency Virus

scholarly journals A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e78289 ◽  
Author(s):  
Muhammed O. Afolabi ◽  
Jorjoh Ndure ◽  
Abdoulie Drammeh ◽  
Fatoumatta Darboe ◽  
Shams-Rony Mehedi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Human Immunodeficiency Virus ◽  
Phase I ◽  
Randomized Clinical Trial ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus

scholarly journals Vitamin A deficiency and behavioral and motor deficits in the human immunodeficiency virus type 1 transgenic rat

2009 ◽  
Vol 15 (5-6) ◽  
pp. 380-389 ◽  
Author(s):  
Harry L June ◽  
Andrew Rong Song Tzeng Yang ◽  
Joseph L Bryant ◽  
Odell Jones ◽  
Walter Royal
Keyword(s):  
Human Immunodeficiency Virus ◽  
Vitamin A ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Vitamin A Deficiency ◽  
Motor Deficits ◽  
Transgenic Rat ◽  
Immunodeficiency Virus

scholarly journals Mutations in Human Immunodeficiency Virus Type 1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross-Resistance to the Clinical Trial Drug GS-9137

2008 ◽  
Vol 52 (6) ◽  
pp. 2069-2078 ◽  
Author(s):  
Anneleen Hombrouck ◽  
Arnout Voet ◽  
Barbara Van Remoortel ◽  
Christel Desadeleer ◽  
Marc De Maeyer ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Cross Resistance ◽  
Strand Transfer ◽  
Immunodeficiency Virus ◽  
Resistance Patterns ◽  
Trial Drug

ABSTRACT To gain further insight into the understanding of the antiviral resistance patterns and mechanisms of the integrase strand transfer inhibitor L-870,810, the prototypical naphthyridine analogue, we passaged the human immunodeficiency virus type 1 strain HIV-1(IIIB) in cell culture in the presence of increasing concentrations of L-870,810 (IIIB/L-870,810). The mutations L74M, E92Q, and S230N were successively selected in the integrase. The L74M and E92Q mutations have both been associated in the past with resistance against the diketo acid (DKA) analogues L-708,906 and S-1360 and the clinical trial drugs MK-0518 and GS-9137. After 20, 40, and 60 passages in the presence of L-870,810, IIIB/L-870,810 displayed 22-, 34-, and 110-fold reduced susceptibility to L-870,810, respectively. Phenotypic cross-resistance against the DKA analogue CHI-1043 and MK-0518 was modest but that against GS-9137 was pronounced. Recombination of the mutant integrase genes into the wild-type background reproduced the resistance profile of the resistant IIIB/L-870,810 strains. In addition, resistance against L-870,810 was accompanied by reduced viral replication kinetics and reduced enzymatic activity of integrase. In conclusion, the accumulation of L74M, E92Q, and S230N mutations in the integrase causes resistance to the naphthyridine L-870,810 and cross-resistance to GS-9137. These data may have implications for cross-resistance of different integrase inhibitors in the clinic.

Sign in / Sign up

Export Citation Format

Share Document